Ingen to debut new Smart Nasal Cannula at 13th Annual Force Health Protection Conference

NewsGuard 100/100 Score

Ingen Technologies, Inc. (Pink Sheets:IGNT), a medical device manufacturer with an emerging new medical product line targeting the $8B respiratory market, announced today that the company's strategic government contract consultant, KGMA Business Solutions, has scheduled two major tradeshows for August and September, 2010.

Ingen will debut its new Smart Nasal Cannula on August 10-11, 2010 at the 13th Annual Force Health Protection Conference (FHP) in Phoenix, Arizona; and again on September 8th, 2010 at the Fort Detrick Vendor Day in Frederick, Maryland.

The FHP Conference provides a venue to educate attendees about health promotion, disease and injury prevention, health risks from occupational and environmental health threats and zoonotic diseases, and related preventive medicine and public health topics in garrison and deployed settings. This event will include representatives from DoD, VA and other U.S. Government agencies, academia, industry partners, and allied nations.

Fort Detrick Vendor Day will host the Defense Medical Materiel Program Office (DMMPO), U.S. Army Medical Materiel Agency (USAMMA), the Naval Medical Logistics Command (NAVMEDLOGCOM), the Air Force Medical Evaluation Support Activity (AFMESA), the Air Force Medical Logistics Office (AFMLO), and the U.S. Marine Corp Systems Command. The focus of this year's venue is on "new" products.

"KGMA Business Solutions has structured an aggressive tradeshow schedule while they work at closing $1.4M in government purchases," said Chairman and CEO Scott R. Sand. "Our marketing program is targeted for $11M in the 2010 fiscal year sales."

CONTACT: Ingen Technologies, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Impact of nirsevimab immunization on pediatric RSV-related hospitalizations in Luxembourg